期刊
BONE MARROW TRANSPLANTATION
卷 50, 期 -, 页码 S11-S13出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2015.88
关键词
-
资金
- WIS-CSP Foundation
- Gilead
- Milteny Biotec
- Gamida cell
- Adienne Pharma and Biotech
- Medac hematology
- Kiadis Pharma
- Almog Diagnostic
Clinical trials have shown that a strategy for haploidentical transplantation based on the infusion of high numbers of T-cell-depleted hematopoietic progenitor cells and no post-transplant immunosuppression controls graft rejection and GvHD in patients with acute leukemia. Overall, event-free survival compares favorably with reports of transplants using sources of stem cells other than the matched sibling. Current studies are focussing on rebuilding post-transplant immunity to improve clinical outcomes separating GvHD from favourable donor immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据